Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial
Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.
Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.
Researchers sought to evaluate results from adults with moderate to severe atopic dermatitis who are treated with abrocitinib after being treated with dupilumab.
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
Important clinical considerations for clinicians treating asthma, rhinitis, and atopic dermatitis are presented.
The ideal duration for obtaining a positive repeated open application test (ROAT) for a topical product is investigated.
The prevalence, incidence, and risk for acne in adolescent and adult patients with atopic dermatitis (AD) is assessed.
A real-world study on the safety and efficacy of dupilumab as a treatment for atopic dermatitis in adolescents was conducted.
There are no differences in effectiveness between the four main types of moisturizers for childhood eczema.
Increased consumption of dietary sodium may increase the risk for atopic dermatitis.
The safety and tolerability of ruxolitinib cream 1.5% for maximum-use in patients with atopic dermatitis is investigated.